The authors engineered pH‑selective CD28×VISTA bispecific antibodies (bsAbs) that engage VISTA on myeloid cells preferentially under acidic tumor microenvironment conditions, co‑stimulating CD28 on T cells only in tumors. In a humanized CD28 syngeneic mouse model, these bispecifics suppressed growth of VISTA‑expressing MC38 tumors, particularly in combination with anti‑PD‑1 therapy.
The bsAb provided tumor-specific CD28 co‑stimulation in the TME, drove T cell activation, controlled tumor growth, and avoided systemic T‑cell activation / cytokine release in peripheral tissues
Humanized CD28 Knockin mouse (syngeneic immunocompetent background, expressing human CD28) — genOway-developed
Cancer immunotherapy, Tumor‑targeted costimulation, Bispecific antibodies, CD28 agonism, VISTA targeting, Myeloid‑mediated activation
Human CD28 gene Knockin (replacing murine CD28), syngeneic tumor implantation (MC38 engineered to express human VISTA), pH‑sensitive binding engineering, in vivo treatment with bsAb ± anti‑PD‑1, T cell activation assays, cytokine panels
From model design to experimental results
Featured in 600+ scientific articles
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Generated with biopharma partners and in-house
and guaranteed freedom to operate
Models with certified health status from professional breeders in US and Europe
